$25.50
-0.13 (-0.51%)
Open$25.02
Previous Close$25.63
Day High$25.96
Day Low$22.92
52W High$38.33
52W Low$2.01
Volume—
Avg Volume360.4K
Market Cap1.73B
P/E Ratio—
EPS$-12.01
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-34.1% upside
Current
$25.50
$25.50
Target
$16.81
$16.81
$13.00
$16.81 avg
$24.93
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.65M | 7.80M | 6.88M |
| Net Income | -2,097,514 | -1,645,262 | -1,540,052 |
| Profit Margin | -27.4% | -21.1% | -22.4% |
| EBITDA | -2,154,773 | -2,236,853 | -1,912,817 |
| Free Cash Flow | -1,120,093 | -988,846 | -1,121,747 |
| Rev Growth | +8.4% | +22.8% | +24.7% |
| Debt/Equity | 0.85 | 0.67 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |